Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Miquel S. Porta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1684-7428; OpenAlex author ID A5065863075. Sources: OpenAlex.

Their work

Papers
33 (first author 4, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
46
Papers, trials and grants by year

2011: 3 papers · 2012: 2 papers · 2013: none · 2014: 2 papers · 2015: 3 papers · 2016: 1 paper · 2017: none · 2018: 3 papers · 2019: 4 papers · 2020: 5 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 3 papers

Papers 33

  1. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  2. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  3. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  4. Factors influencing the diagnostic basis in pancreatic cancer. A study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Co-author DOI 10.1016/j.ctarc.2025.101009↗
  5. Circulating per- and polyfluoroalkyl substances and risk of pancreatic cancer: A nested case-control study within the NYU Women's health study. First author DOI 10.1016/j.envpol.2025.127185↗
  6. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  7. Timing of Toenail Collection and Concentrations of Metals in Pancreatic Cancer. Evidence Against Disease Progression Bias. Co-author DOI 10.1007/s12403-021-00436-2↗
  8. Plasma concentrations of persistent organic pollutants and pancreatic cancer risk. Co-author DOI 10.1093/ije/dyab115↗
  9. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Co-author DOI 10.1093/ajcn/nqab217↗
  10. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  11. Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.envres.2020.109781↗
  12. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  13. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  14. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  15. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0651↗
  16. Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/em.22296↗
  17. Toenail concentrations of trace elements and occupational history in pancreatic cancer. Last author DOI 10.1016/j.envint.2019.03.037↗
  18. Methodological issues in a prospective study on plasma concentrations of persistent organic pollutants and pancreatic cancer risk within the EPIC cohort. Last author DOI 10.1016/j.envres.2018.11.027↗
  19. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy155↗
  20. Circulating plasma phospholipid fatty acids and risk of pancreatic cancer in a large European cohort. Co-author DOI 10.1002/ijc.31797↗
  21. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  22. The Association of Recently Diagnosed Diabetes and Long-term Diabetes With Survival in Pancreatic Cancer Patients: A Pooled Analysis. Co-author DOI 10.1097/mpa.0000000000000989↗
  23. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  24. A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2015/587250↗
  25. Vitamin D metabolic pathway genes and pancreatic cancer risk. Co-author DOI 10.1371/journal.pone.0117574↗
  26. Correction: vitamin d metabolic pathway genes and pancreatic cancer risk. Co-author DOI 10.1371/journal.pone.0129983↗
  27. Adjusting serum concentrations of organochlorine compounds by lipids and symptoms: a causal framework for the association with K-ras mutations in pancreatic ca… Last author DOI 10.1016/j.chemosphere.2014.04.066↗
  28. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  29. Pancreatic cancer risk and levels of trace elements. First author DOI 10.1136/gutjnl-2011-301086↗
  30. Relationships of hepatic and pancreatic biomarkers with the cholestatic syndrome and tumor stage in pancreatic cancer. Co-author DOI 10.3109/1354750x.2012.701331↗
  31. Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patien… First author DOI 10.1007/s10654-011-9547-8↗
  32. How useful is it clinically to analyse the K-ras mutational status for the diagnosis of exocrine pancreatic cancer? A systematic review and meta-analysis. Last author DOI 10.1111/j.1365-2362.2011.02495.x↗
  33. Relationships between occupational history and serum concentrations of organochlorine compounds in exocrine pancreatic cancer. First author DOI 10.1136/oem.2009.054197↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. José A. Pumarega · 8 shared papers, 2012–2025 · strength 0.73
  2. Magda Gasull · 6 shared papers, 2011–2025 · strength 0.65
  3. Yu Chen · 2 shared papers, 2022–2025 · strength 0.36
  4. Judit Camargo · 3 shared papers, 2019–2022 · strength 0.34
  5. André F.S. Amaral · 4 shared papers, 2012–2020 · strength 0.33
  6. Núria Malats · 5 shared papers, 2011–2019 · strength 0.24
  7. Paolo Vineis · 2 shared papers, 2018–2025 · strength 0.23
  8. Verena Andrea Katzke · 2 shared papers, 2018–2025 · strength 0.23
  9. Fen Wu · 1 shared paper, 2025 · strength 0.22
  10. María‐Dolores Chirlaque · 1 shared paper, 2025 · strength 0.18
  11. Sandra Milena Colorado-Yohar · 1 shared paper, 2025 · strength 0.18
  12. Marta Crous‐Bou · 1 shared paper, 2025 · strength 0.18
  13. Pietro Ferrari · 1 shared paper, 2025 · strength 0.18
  14. Esteve Fernández · 2 shared papers, 2011–2022 · strength 0.16
  15. Tomás López‐Jiménez · 5 shared papers, 2011–2014 · strength 0.16
  16. Francisco X. Real · 4 shared papers, 2011–2015 · strength 0.14
  17. Álvaro Gómez‐Tomás · 1 shared paper, 2019 · strength 0.10
  18. Lawrence S. Engel · 1 shared paper, 2020 · strength 0.10
  19. Jeanine M. Genkinger · 1 shared paper, 2020 · strength 0.10
  20. Sara H. Olson · 1 shared paper, 2018 · strength 0.08
  21. Rayjean J. Hung · 1 shared paper, 2018 · strength 0.08
  22. Sean Patrick Cleary · 1 shared paper, 2018 · strength 0.08
  23. Adetunji T. Toriola · 1 shared paper, 2018 · strength 0.08
  24. Cristina Bosetti · 1 shared paper, 2018 · strength 0.08
  25. Rachael Z. Stolzenberg‐Solomon · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.